Dishman Carbogen Amcis

NSE: DCALBSE: 540701
Compare with peers
₹ 149.00▲ 1.3 (+0.88%)28 Oct, 03:29 pm IST
Market cap
₹ 2,135 Cr.
P/E
128.7x
P/B
0.33x
52-week range
128.5 – 303
ROE
2%
ROCE
3%
Dividend yield
0%
Debt / equity
0.46
Sector
Pharmaceuticals & Biotechnology
Industry
Pharmaceuticals
Listed on
NSE, BSE

About

Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Pharmaceuticals: 221 companies →

Dishman Carbogen Amcis against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)128.7 against a typical 34.3: pricier than most peers (1st = cheapest).200th of 220
  • Sales growth−4.2% against a typical +15.6% from a year earlier.155th of 197
  • Profit growth−352.2% against a typical +18.9% from a year earlier.157th of 160
  • Share price, 3 months−20.7% against a typical −0.5%.181st of 200
  • Size₹ 2,134.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).68th of 199

Latest announcements

Exchange filings and their impact on the company.

  • 15 Oct 2026Allotment of SecuritiesLow impactNeutralPrice −1.2% that day
    Dishman allotted Rs 38 cr of secured NCDs due April 2028, marginally raising debt.

    Dishman Carbogen Amcis allotted 3,800 senior, secured, rated, listed NCDs of Rs 1 lakh each, raising Rs 38 crore via private placement on 15 October 2026. The debentures mature on 15 April 2028. The amount is small versus existing borrowings of over Rs 3,000 crore, so it only marginally increases debt and interest cost.

    Filing
  • 7 Oct 2026Outcome of Board MeetingLow impactNegativePrice −0.7% that day
    Board approved a small Rs 38 cr 10% secured NCD issue and swapping land security for cash on existing Rs 15 cr NCDs.

    On 7 Oct 2026 Dishman Carbogen Amcis board approved issuing up to Rs 38 crore of 18-month, 10% senior secured NCDs by private placement, secured 1.1x by promoter Dishman Infrastructure land, its corporate guarantee and a 3-month interest reserve. It also approved replacing Dishman Infrastructure's land mortgage for the Rs 15 crore NCDs allotted 28 Sep 2026 with 100% cash margin as fixed-deposit lien. The amounts are small against Rs 3,076 crore borrowings and add about Rs 3.8 crore in annual interest while locking up Rs 15 crore cash.

    Filing

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

No up-to-date rating

AgencyCurrent ratingOutlookAs of
India RatingsWithdrawnNegative4 Jun 2026

Every agency has withdrawn its rating.

Credit rating actions
RatingDetails
4 Jun 2026
Withdrawn
was IND A—India Ratings₹ 1,060.8 Cr.
18 Feb 2026
Withdrawn
was IND A—India Ratings₹ 1,060.9 Cr.

Board meetings

Results dates and other board meetings. Full calendar

Details
7 Oct 2026Fund Raising/Other business mattersTo consider Fund Raising and other business matters
14 Aug 2026Financial ResultsTo consider and approve the un-audited financial results for the period ended June 30, 2026
12 Aug 2026Fund RaisingTo consider Fund Raising
19 May 2026Financial Results/Other business mattersTo consider and approve the financial results for the period ended March 31, 2026 and other business matters
18 Mar 2026Fund RaisingTo consider Fund Raising
3 Feb 2026Financial ResultsTo consider and approve the financial results for the period ended December 31, 2025

Share price

1Y change −49.21%
0 of 2 filing days came with a big price move
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales587651655524789682716708653720851678
Expenses526610592495642542564567504607688618
Operating Profit6141632914714015314114911316360
OPM %10%6%10%6%19%21%21%20%23%16%19%9%
Other Income564−448−422871516
Interest273331323749424342464337
Depreciation758085717272798184848991
Profit before tax−36−66−49−784227283931−1046−51
Tax %13%−10%42%0%21%83%−56%39%−114%24%53%13%
Net Profit−41−60−70−78335432365−1322−58
EPS in Rs−2.61−3.8−4.46−4.952.110.32.751.494.16−0.831.39−3.69

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
—
5 Years
9%
3 Years
7%
TTM
0%
Compounded Profit Growth
10 Years
—
5 Years
21%
3 Years
140%
TTM
−85%
Stock Price CAGR
10 Years
—
5 Years
−1%
3 Years
4%
TTM
—
Return on Equity
10 Years
1%
5 Years
0%
3 Years
0%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
59.32%
0 pts in a year
FIIs
6.86%
−3.08 pts in a year
DIIs
2.06%
+0.79 pts in a year
Public
31.76%
+2.28 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 128.7xEPS (12 months) ₹ 1.16Median P/E 32.2x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Dishman Carbogen Amcis₹ 149.00₹ 2,135 Cr.128.7x0.3x2%—
Sun Pharmaceutical Industries₹ 1,743.00₹ 4,18,194 Cr.38.4x5.6x14.2%19.1%
Divi's Laboratories₹ 8,984.00₹ 2,38,497 Cr.73.3x11.5x16.2%24.3%
Torrent Pharmaceuticals₹ 4,482.00₹ 1,70,475 Cr.72.7x19.2x27.1%15.3%
Cipla₹ 1,337.00₹ 1,08,011 Cr.27.6x3.3x11.8%13.7%
Zydus Lifesciences₹ 1,127.85₹ 1,12,503 Cr.21.2x4.2x19.7%18.5%

Management

Harshil R. Dalal
Global Chief Financial Officer
Shrima Gaurangbhai Dave
Compliance Officer, Company Secretary
Arpit Janmejay Vyas
Global Managing Director, Executive Director
Deohooti Janmejay Vyas
Whole-Time Director

Prices are delayed and for information only. Nothing on this page is investment advice.